Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F901318 Phase I Safety and PK Study in Healthy Males
NCT02342574Phase 1Completed
- Sponsor
- F2G
- Start
- Feb 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olorofim in invasive aspergillosis (IA) (18 arms), sponsored by F2G. Primary endpoint: Adverse Events at 13 days. Started Feb 2015; status: completed.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT02342574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342574.